Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 54Breast Neoplasms 43Neoplasms 4Salivary Gland Neoplasms 3Triple Negative Breast Neoplasms 2Prostate Adenocarcinoma 2Advanced Breast Cancer 2Recurrence 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphatic Metastasis 1Inflammatory Breast Neoplasms 1Hormone-sensitive Metastatic Breast Cancer 1Hormone Sensitive Prostate Cancer 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Fallopian Tube Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms, Male 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Trastuzumab 11pyrotinib 8pertuzumab 5Docetaxel 5trastuzumab deruxtecan 2Paclitaxel 2Carboplatin 2Capecitabine 2tucatinib 1pegfilgrastim 1neratinib 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1atezolizumab 1Neoadjuvant Therapy 1Metformin 1Leuprolide 1Goserelin 1Fulvestrant 1Drug Therapy 1Anastrozole 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HER2-positive Breast Cancer × Goserelin × Clear all
NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Fudan University

Phase 2 Not yet recruiting
288 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡